These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39167623)

  • 1. Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
    Saba NF; Chaudhary R; Kirtane K; Marra A; Ekpenyong A; McCook-Veal A; Schmitt NC; Gross JH; Patel MR; Remick J; Bates JE; McDonald MW; Rudra SF; Stokes WA; Biernacki M; Song X; Slebos RJC; Liu Y; Steuer CE; Shin DM; Teng Y; Chung CH
    Clin Cancer Res; 2024 Oct; 30(20):4601-4608. PubMed ID: 39167623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
    Desilets A; Pfister DG; Stein S; Wong W; Sherman EJ; Fetten J; Hung TKW; Kriplani A; Dunn LA; Ho AL; Michel LS
    Oral Oncol; 2024 Jul; 154():106861. PubMed ID: 38795600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
    Saba NF; Steuer CE; Ekpenyong A; McCook-Veal A; Magliocca K; Patel M; Schmitt NC; Stokes W; Bates JE; Rudra S; Remick J; McDonald M; Abousaud M; Tan AC; Fadlullah MZH; Chaudhary R; Muzaffar J; Kirtane K; Liu Y; Chen GZ; Shin DM; Teng Y; Chung CH
    Nat Med; 2023 Apr; 29(4):880-887. PubMed ID: 37012550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
    Iwaki S; Kadowaki S; Honda K; Narita Y; Masuishi T; Taniguchi H; Ando M; Muro K; Sawabe M; Suzuki H; Nishikawa D; Beppu S; Terada H; Kishikawa T; Kawakita D; Hanai N
    Int J Clin Oncol; 2024 Jun; 29(6):764-770. PubMed ID: 38555323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
    Cho BC; Braña I; Cirauqui B; Aksoy S; Couture F; Hong RL; Miller WH; Chaves-Conde M; Teixeira M; Leopold L; Munteanu M; Ge JY; Swaby RF; Hughes BGM
    BMC Cancer; 2024 Jul; 23(Suppl 1):1254. PubMed ID: 39054467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
    Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
    Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
    Taylor MH; Betts CB; Maloney L; Nadler E; Algazi A; Guarino MJ; Nemunaitis J; Jimeno A; Patel P; Munugalavadla V; Tao L; Adkins D; Goldschmidt JH; Cohen EEW; Coussens LM
    Clin Cancer Res; 2022 Mar; 28(5):903-914. PubMed ID: 34862248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
    Dzienis M; Cundom J; Fuentes CS; Spreafico A; Nordlinger M; Pastor AV; Alesi E; Neki A; Fung AS; Figueiredo Lima IP; Oppelt P; da Cunha Junior GF; Burtness B; Franke FA; Tseng JE; Joshi A; McCarthy J; Swaby R; Sidi Y; Gumuscu B; Naicker N; de Castro G
    J Clin Oncol; 2024 Sep; 42(25):2989-2999. PubMed ID: 39038265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
    Hagiwara K; Matsuki T; Okada T; Fushimi C; Kondo T; Takahashi H; Okamoto I; Tokashiki K; Hanyu K; Kishida T; Ito T; Yamashita G; Tsukahara K; Masubuchi T; Tada Y; Momiyama K; Yaguchi R; Oridate N; Omura GO; Yamashita T
    Anticancer Res; 2024 Sep; 44(9):4057-4072. PubMed ID: 39197913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Chiu TJ; Huang TL; Chien CY; Huang WT; Li SH
    World J Surg Oncol; 2024 Sep; 22(1):242. PubMed ID: 39256833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
    Jackovich A; Gitlitz BJ; Tiu-Lim JWW; Duddalwar V; King KG; El-Khoueiry AB; Thomas JS; Tsao-Wei D; Quinn DI; Gill PS; Nieva JJ
    Oncotarget; 2024 Jul; 15():444-458. PubMed ID: 38985143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.
    Forster M; Brana I; Pousa AL; Doger B; Roxburgh P; Bajaj P; Peguero J; Krebs M; Carcereny E; Patel G; Mueller C; Brignone C; Triebel F
    Clin Cancer Res; 2024 Sep; 30(17):3726-3734. PubMed ID: 38995265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.
    Adkins D; Ley JC; Liu J; Oppelt P
    Lancet Oncol; 2024 Jul; 25(7):888-900. PubMed ID: 38851207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.